Observational studyThe lancet. Gastroenterology & hepatology2023

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

Zhigang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.